Recombinant Mouse A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) Protein (hFc)
Beta LifeScience
SKU/CAT #: BLC-07118P
Greater than 85% as determined by SDS-PAGE.
Recombinant Mouse A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) Protein (hFc)
Beta LifeScience
SKU/CAT #: BLC-07118P
Collections: Enzymes, Featured enzyme molecules, Protease, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Mouse A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) Protein (hFc) is produced by our Mammalian cell expression system. This is a protein fragment. |
Purity | Greater than 85% as determined by SDS-PAGE. |
Uniprotkb | Q769J6 |
Target Symbol | ADAMTS13 |
Species | Mus musculus (Mouse) |
Expression System | Mammalian cell |
Tag | C-hFc |
Target Protein Sequence | WTPLVGLCSISCGRGLKELYFLCMDSVLKMPVQEELCGLASKPPSRWEVCRARPCPARWETQVLAPCPVTCGGGRVPLSVRCVQLDRGHPISVPHSKCSPVPKPGSFEDCSPEPCPARWKVLSLGPCSASCGLGTATQMVACMQLDQGHDNEVNETFCKALVRPQASVPCLIADCAFRWHISAWTECSVSCGDGIQRRHDTCLGPQAQVPVPANFCQHLPKPMTVRGCWAGPCA |
Expression Range | 904-1137aa |
Protein Length | Partial |
Mol. Weight | 54.2 kDa |
Research Area | Cancer |
Form | Liquid or Lyophilized powder |
Buffer | Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. |
Reconstitution | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
Storage | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
Notes | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
Target Details
Target Function | Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation. |
Subcellular Location | Secreted. |
Database References | |
Tissue Specificity | Plasma. Expression is consistently high in liver, medium in lung and spleen, low in skeletal muscle and undetectable in heart, brain, kidney and testis. |
Gene Functions References
- ADAMTS13-vWF axis is partially involved in the pathophysiology of kidney ischemic reperfusion injury. PMID: 27507004
- Adamts13 deficiency in obese mice promotes hepatic microthrombosis. PMID: 27604194
- results suggest that ADAMTS13 controls key steps of ischemic vascular remodeling and that recombinant ADAMTS13 is a putative therapeutic avenue for promoting stroke recovery. PMID: 28428179
- ADAMTS13 retards progression of diabetic nephropathy, most likely by inhibiting VWF-dependent intrarenal thrombosis. PMID: 28495930
- administration of ADAMTS13 5 minutes after occlusion dose-dependently dissolved these t-PA-resistant thrombi resulting in fast restoration of MCA patency and consequently reduced cerebral infarct sizes PMID: 26929275
- Sleeping beauty transposon-mediated gene therapy achieved sustained expression of transgene ADAMTS13 and long-term prophylaxis against congenital thrombotic thrombocytopenic purpura in Adamts13(-/-) mice. PMID: 28254814
- Results also suggest that Toxoplasma gondii-mediated apoptosis might play a pivotal role and a different type of role in the mechanism of neurodegeneration and neuropathology in the process of toxoplasma encephalitis. Furthermore, expression of ADAMTS-13 might give an idea of the progress and is critical for diagnosis of this disease. PMID: 26542631
- Letter: deficiency of ADAMTS13 results in increased formation of venous thrombosis in mice. PMID: 25855507
- ADAMTS13 substrate specificity PMID: 25849793
- Data indicate that the p.D187H mutation impairs ADAMTS13 activity and secretion and may contribute to thrombotic thrombocytopenic purpura. PMID: 25442981
- Data show that metalloendopeptidase ADAMTS13 does not directly promote development of adipose tissue. PMID: 25813552
- findings provide further evidence on the pathophysiological role for the ADAMTS13/VWF axis in atherosclerosis PMID: 24261607
- Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner. PMID: 24357063
- Three novel mutations in a homozygous state were identified in these patients: c.1308G>C, c.428T>C (p.Ile143Thr) and c.1709A>G (p.Tyr570Cys) PMID: 24115559
- The results indicate that the microvascular process induced by ADAMTS13 deficiency triggers complement activation on platelets and the endothelium, which may contribute to formation of thrombotic microangiopathy. PMID: 23878316
- model of acute myocardial infarction in ADAMTS13 gene deleted (Adamts13 -/-) mice PMID: 23051932
- We hypothesize that ADAMTS13 protects brain from ischemia-reperfusion injury by regulating von Willebrand factor -dependent inflammation as well as microvascular plugging PMID: 22212812
- Cyclophilin B activity regulated secretion and activity of ADAMTS13. PMID: 23144461
- Adamts13(-/-) mice developed larger myocardial infarctions than wild-type control mice. PMID: 22915644
- ADAMTS13 and VWF are causally involved in myocardial ischemia/reperfusion injury. PMID: 22983446
- We revealed the epitopes of 11 monoclonal anti-ADAMTS13 antibodies on each of the domains and clarified their association with inhibitory effects on VWF catalysis under static conditions. PMID: 22721582
- Provide new evidence for ADAMTS13 in reducing VWF-mediated acute cerebral inflammation following ischemic stroke. PMID: 22712744
- ADAMTS13 plays a critical role in modulating the development of early atherosclerosis. PMID: 22652598
- Prophylactic administration of 200 units/kg recombinant human ADAMTS13 protected ADAMTS13 knockout mice from developing thrombotic thrombocytopenic purpura. PMID: 22529289
- Gender-dependent up-regulation of ADAMTS-13 in mice with obesity and hypercholesterolemia. PMID: 22192156
- Findings suggest a new functional role for the antithrombotic enzyme ADAMTS13 in reducing excessive vascular inflammation and plaque formation during early atherosclerosis. PMID: 22123843
- Results suggest that the amino terminus of ADAMTS13, specifically the variable region of the spacer domain, is crucial for modulation of arterial thromboses under (patho)physiological conditions. PMID: 21799176
- Glomerular endothelial cells express and secrete ADAMTS13. PMID: 21720563
- in vivo imaging analysis revealed that ADAMTS13 regulates the disappearance of platelet strings on DDAVP-stimulated VECs and on the FeCl3-injured venous vascular wall through the cleavage of UL-VWF. PMID: 21494805
- ADAMTS13 CUB and T2-8 domains influence proteolysis of platelet-decorated VWF strings in vivo PMID: 20695979
- von Willebrand factor clearance does not involve proteolysis by ADAMTS-13 PMID: 20704649
- Shiga toxin B subunits induce thrombotic microangiopathy in Adamts13(-/-) mice. PMID: 20644116
- Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. PMID: 20200350
- ADAMTS13 down-regulates platelet adhesion and aggregation in vivo, and ADAMTS13 deficiency can provide enhanced thrombus formation at the site of vascular lesions in mice PMID: 20047094
- ADAMTS13 may protect the brain from ischemia by regulating VWF-platelet interactions after reperfusion. PMID: 19965676
- analysis of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease PMID: 15136581
- Identification of the liver cell-type expressing ADAMTS13 will have is important for understanding pathophysiological mechanisms regulating ADAMTS13 expression. PMID: 15806136
- characterization of the full-length murine ADAMTS13 PMID: 15869605
- REVIEW: the nature of ADAMTS13's interaction with von Willebrand factor and the pathogenesis of clinical thrombotic thrombocytopenic purpura, especially in relation to ADAMTS13 PMID: 17414218
- REVIEW: Accumulated clinical information on patients with ADAMTS13 deficiency and mice lacking the Adamts13 gene indicates that additional environmental or genetic susceptibility factors are required to trigger thrombotic thrombocytopenic purpura. PMID: 17414219
- the plasma ADAMTS13 activity levels of mouse strains segregated into a high and a low group. Low ADAMTS13 activity was detected in mice containing 2 alleles of intracisternal A-type particle (IAP) retrotransposon sequence PMID: 17426255
- Imbalance between the blood von Willebrand factor and ADAMTS13 levels may occur in endotoxinemia, which may partly contribute to the thrombotic state associated with endotoxinemia. PMID: 18006046
- the potential roles played by ADAMTS13 and VWF in TTP, endotoxemia, and normal hemostasis. PMID: 18083848
- a new mechanism of anthrax coagulopathy affecting the levels and functional activities of both VWF and its natural regulator ADAMTS13. This mechanism may contribute to hemorrhage and thrombosis typical in anthrax. PMID: 18263586
- ADAMTS13 has an important role in preventing excessive spontaneous Weibel-Palade body secretion, and in the regulation of leukocyte adhesion and extravasation during inflammation PMID: 18695007
- the C-terminally truncated ADAMTS13 exhibited decreased activity in the cleavage of VWF under high shear rate and accelerated thrombogenesis PMID: 19109562
- von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. PMID: 19687510